To contentTo navigationTo search
Logotype

Investors

Press releases

Press releases

2021

Implantica has decided to proceed with a private placement of SDRs raising gross proceeds of approximately SEK 600 million

15.04.2021
 | Regulatory
Implantica AG (ticker: IMP A SDB) (“Implantica” or the “Company”) has decided to proceed with a private placement of 4,900,000 newly issued Class A shares represented by Swedish Depository Receipts (“SDRs”) at a subscription price of SEK 122.20 per SDR (the “Private Placement”). The Private Placement is subject to the board of directors formally resolving on the Private Placement following the authorization to be granted by the Annual General Meeting (the “AGM”) on 16 April 2021. The subscription price per SDR in the Private Placement was determined through an accelerated book building procedure conducted by Pareto Securities AB (the “Sole Global Coordinator and Bookrunner”). The Private Placement was multiple times over-subscribed and was directed to a number of new and existing institutional investors, including DNCA Investments, Handelsbanken Fonder, Invus, Swedbank Robur Fonder and TIN Fonder.

Implantica avser genomföra en riktad nyemission av svenska depåbevis

15.04.2021
 | Regulatory
Implantica AG (ticker: IMP A SDB) (”Implantica” eller ”Bolaget”) har gett i uppdrag till Pareto Securities att utvärdera möjligheterna att genomföra en riktad nyemission av svenska depåbevis (”SDB”) om cirka 500 miljoner SEK (den ”Riktade Nyemissionen”) till svenska och internationella institutionella investerare genom ett accelererat bookbuilding-förfarande.

Implantica contemplates a private placement of SDRs

15.04.2021
 | Regulatory
Implantica AG (ticker: IMP A SDB) (“Implantica” or the “Company”) has mandated Pareto Securities to evaluate the conditions for a private placement of SDRs corresponding to approximately SEK 500 million (the “Private Placement”), to Swedish and international institutional investors through an accelerated book building procedure.

Notice of Annual General Meeting of Implantica AG

29.03.2021
 | Regulatory
The shareholders of Implantica AG (publ), reg. no. FL-0002.629.889-3, are hereby given notice of the annual general meeting on Friday, April 16, 2021, at 11:00 CET.

Implantica publicerar årsredovisning 2020

24.03.2021
 | Regulatory
Implantica AG (publ) publicerar sin årsredovisning för räkenskapsåret 2020. Årsredovisningen finns nu tillgänglig på bolagets hemsida.

Implantica publishes Annual Report 2020

24.03.2021
 | Regulatory
Implantica AG (publ) is publishing its annual report for the fiscal year 2020. The annual report is now available on the company’s website.

Implantica announces a milestone achieved for its implantable medical device RefluxStop™

23.03.2021
 | Other press releases
Implantica AG (publ) today announces that one of the largest hospitals in Europe, University Hospital AKH Vienna, will soon commence a study of RefluxStop™ with 25-30 reflux patients, conducted under the direction of Prof. Dr. med. Sebastian Schoppmann.

Implantica meddelar att en milstolpe uppnåtts för deras medicinska implantat RefluxStop™

23.03.2021
 | Other press releases
Implantica AG (publ) offentliggör idag att ett av Europas största Universitetssjukhus, AKH Wien, kommer snart påbörja en studie av RefluxStop™ omfattande 25-30 reflux patienter, utförda under ledning av Prof. Dr. med. Sebastian Schoppmann.

Implantica makes headway in Italy and Spain with its medical device RefluxStop™

15.03.2021
 | Other press releases
Implantica AG (publ) today announces that the company will start commercializing RefluxStop™ on a reimbursed basis in Italy and Spain based on local/regional hospital agreements.

Implantica gör framsteg i Italien och Spanien med sitt medicinska implantat RefluxStop ™

15.03.2021
 | Other press releases
Implantica AG (publ) meddelar idag att bolaget kommer börja kommersialisera RefluxStop™ i Italien och Spanien med ersättning av den offentliga sjukvården baserat pa lokala/regonala avtal med sjukhusen.
Load more